Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 8/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 8/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 8/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | CNR2 | P34972 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7054219 | 0.94 | PDE4A (0.89) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL7056840 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL7051846 | 0.90 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL7051841 | 0.89 | PDE4A (0.80) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL7051824 | 0.89 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL7056993 | 0.88 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| Hydrochloric Acid SCHEMBL7058569 | 0.88 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL7051840 | 0.87 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL7050614 | 0.86 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL7052437 | 0.85 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4DMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0841929-B1 | QUINOLONES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LTD (GB) | 2003-05-07 | — | — | EP | claimed |
| US-7354941-B2 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PRODUCTS INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354941-B2 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PRODUCTS INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7250518-B2 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250518-B2 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1229034-B1 | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes | PFIZER PROD INC (US) | 2005-04-13 | — | — | EP | disclosed |
| EP-0841929-B1 | QUINOLONES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LTD (GB) | 2003-05-07 | — | — | EP | disclosed |
| US-5891878-A | Quinolones and their therapeutic use | CHIROSCIENCE LIMITED (GB) | 1999-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PDE4A, PDE4B, PDE4D | PDE4A 1/4885PDE4B 2/4885PDE4C 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.